Rubius Prepares Off-The-Shelf Red Cell Therapies For First Human Trial In 2018
Executive Summary
Emerging Company Profile: Rubius Therapeutics is developing genetically engineered red blood cells and has raised $145m to take its first off-the-shelf, long-acting Red Cell Therapeutic into the clinic in 2018.
You may also be interested in...
Finance Watch: Biopharma Reckoning Brings Restructuring Plans, Consolidation
With cash preservation in mind, Rubius will dissolve, while EQRx, Impel, Cybin and Graphite cut jobs. Meanwhile, Jounce is restructuring and it plans to merge with Redx, yet the dually troubled firms MEI Pharma and Infinity will combine, while VBL will disappear in a reverse merger with Notable Labs.
Seagen Taps Epstein As New CEO After A Tumultuous Year
Former Novartis executive and venture capitalist David Epstein will step in to lead Seagen after its founder resigned in a scandal and amid M&A speculation.
IPO Update: Returns Run Red For Most Biopharma Firms That Went Public In The US Last Year
Nearly two-thirds of the 67 drug developers that launched an IPO in 2018 were trading below their offering price at the end of the year, bringing the average return to -7.5%. Even so, biopharma companies continue to line up for a US stock market debut.